Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 11000 participants.

Also called NCT07181109

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 11,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07181109
  • EU CT 2025-522960-34-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Italy, Japan, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07181109. Randomized; quadruple masking; primary purpose treatment. Start 2025-09-06 (actual); primary completion 2030-09-23 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Acronym
ZENITH
Condition
High Risk Cardiovascular Disease
Condition
Hypertension
Condition
High Cardiovascular Risk
Intervention (Drug)
Zilebesiran
Intervention (Drug)
Placebo
Lead sponsor
Alnylam Pharmaceuticals (class: industry)
Collaborator
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct07181109
Content hash
5b758b4ece046b07850dcf9f11d1f07aa5b2d5b3829567f5e9df2f6e87365358